Enhanced multivalent vaccine responses using a novel vaccine vector system

使用新型疫苗载体系统增强多价疫苗反应

• 批准号: LP160100633
• 负责人: Prof John Hayball
• 金额: $ 25.2万
• 依托单位: University of South Australia
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-08-23 至 2019-08-22
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP160100633
• 关键词: Enhanced; multivalent; vaccine; responses; using

Enhanced multivalent vaccine responses using a novel vaccine vector system. This project aims to develop a multicomponent vaccine system to deliver equal effectiveness against several disease targets in a single administration. New and innovative vaccine design strategies incorporating economical commercial production processes are urgently needed for new and existing human and animal health applications. A vaccine capable of targeting multiple diseases by a single injection is an obvious way to expedite future vaccine development and deployment. However, the recipient’s immune system can repress equivalent responses to these multicomponent vaccines. This project’s research is expected to address these problems, and underpin the future commercial development of this vaccine platform.

使用新型疫苗载体系统增强多价疫苗反应。该项目旨在开发一种多组分疫苗系统，以便在一次给药中对几种疾病目标提供同等效力。新的和现有的人类和动物健康应用迫切需要新的和创新的疫苗设计战略，其中包括经济的商业生产过程。一次注射就能针对多种疾病的疫苗是加快未来疫苗开发和部署的明显方式。然而，接受者的免疫系统可以抑制对这些多组分疫苗的同等反应。该项目的研究有望解决这些问题，并为该疫苗平台未来的商业发展奠定基础。